Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
This study is designed to determine if treatments with the combination of HRS-8080 and SHR-A1811, the combination of HRS-8080 and SHR-A2009, the combination of SHR-A2009 and SHR-1316 are safe, tolerable, and has anti-cancer activity in patients with unresectable or metastatic breast cancer.
Breast Cancer
DRUG: HRS-8080; SHR-A1811|DRUG: HRS-8080; SHR-A2009|DRUG: SHR-A2009; SHR-1316
Dose Limited Toxicity（DLT）, Phase 1, up to 1 cycle (21 days)|Maximum Tolerable Dose（MTD）, Phase 1, up to 1 cycle (21 days)|Recommended Phase 2 Dose（RP2D）, Phase 1, up to 1 cycle (21 days)|Safety endpoints: the incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (rated based on CTCAE V5.0), Phase 1, up to 12 months|Efficacy endpoint: objective response rate (ORR), Phase 2, up to 12 months
level of SHR-A1811 ADA and Nab, Phase 1, up to 12 months|level of SHR-A2009 ADA and Nab, Phase 1, up to 12 months|level of adebrelimab ADA and Nab, Phase 1, up to 12 months|Objective response rate (ORR), Phase 1, up to 12 months|Best overall response (BOR), Phase 1, up to 12 months|Duration of response (DoR), Phase 1, up to 12 months|Disease control rate (DCR), Phase 1, up to 12 months|Clinical benefit rate (CBR), Phase 1, up to 12 months|Progression-free survival (PFS), Phase 1, up to 12 months|Safety endpoints: incidence and severity of AEs and SAEs (rated based on CTCAE V5.0), Phase 2, up to 12 months|level of SHR-A1811 ADA and Nab, Phase 2, up to 12 months|level of SHR-A2009 ADA and Nab, Phase 2, up to 12 months|level of adebrelimab ADA and Nab, Phase 2, up to 12 months|Best overall response (BOR), Phase 2, up to 12 months|Duration of response (DoR), Phase 2, up to 12 months|Disease control rate (DCR), Phase 2, up to 12 months|Clinical benefit rate (CBR), Phase 2, up to 12 months|Progression-free survival (PFS), Phase 2, up to 12 months
This study is designed to determine if treatments with the combination of HRS-8080 and SHR-A1811, the combination of HRS-8080 and SHR-A2009, the combination of SHR-A2009 and SHR-1316 are safe, tolerable, and has anti-cancer activity in patients with unresectable or metastatic breast cancer.